Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207M
-
Number of holders
-
120
-
Total 13F shares, excl. options
-
77.2M
-
Shares change
-
+3.05M
-
Total reported value, excl. options
-
$75.7M
-
Value change
-
-$1.56M
-
Put/Call ratio
-
0.17
-
Number of buys
-
57
-
Number of sells
-
-50
-
Price
-
$0.98
Significant Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q3 2023
154 filings reported holding ESPR - Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2023.
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) has 120 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 77.2M shares
of 207M outstanding shares and own 37.23% of the company stock.
Largest 10 shareholders include WASATCH ADVISORS LP (11.5M shares), Two Seas Capital LP (7.67M shares), MILLENNIUM MANAGEMENT LLC (5.79M shares), VANGUARD GROUP INC (4.74M shares), Bellevue Group AG (4.2M shares), Meditor Group Ltd (3.79M shares), PLATINUM INVESTMENT MANAGEMENT LTD (3.19M shares), Point72 Asset Management, L.P. (3.1M shares), JACOBS LEVY EQUITY MANAGEMENT, INC (2.26M shares), and MORGAN STANLEY (2.1M shares).
This table shows the top 120 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.